- Collaboration combines Daiichi Sankyo's scientific and technological excellence with AstraZeneca's global experience and resources in oncology to accelerate and expand the potential of [fam-] ...
- Global regulatory submission for the antibody drug conjugate is based on the pivotal phase 2 DESTINY-Breast01 and phase 1 trials TOKYO, MUNICH and BASKING RIDGE, New Jersey, Sept. 9, 2019 ...
Daiichi Sankyo and AstraZeneca will jointly develop and commercialize [fam-] trastuzumab deruxtecan as a monotherapy or a combination therapy worldwide, except in Japan where Daiichi Sankyo will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results